NextPlat (NXPL) EBT Margin Growth (3y) (2018 - 2026)
Powered by 
Analysis
NextPlat (NXPL) EBT Margin Growth (3y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.34 Bn | 38.68 Bn | 2.15 Bn | 1,282.00 |
| 2 | Viatris | 19.39 Bn | 18.50 Bn | 1.46 Bn | -1,020.00 |
| 3 | Dr Reddys Laboratories | 9.99 Bn | 9.85 Bn | 396.53 Mn | -2,093.00 |
| 4 | Amneal Pharmaceuticals | 5.57 Bn | 5.53 Bn | 334.51 Mn | 396.00 |
| 5 | Bausch Health Companies | 2.45 Bn | 1.58 Bn | 2.10 Bn | 856.00 |
| 6 | Ani Pharmaceuticals | 1.70 Bn | 1.34 Bn | 165.89 Mn | 944.00 |
| 7 | Alvotech | 1.66 Bn | 1.52 Bn | 2.56 Mn | -258,655.00 |
| 8 | Amphastar Pharmaceuticals | 985.90 Mn | 695.77 Mn | 93.47 Mn | -156.00 |
| 9 | Fennec Pharmaceuticals | 434.07 Mn | 392.82 Mn | 17.15 Mn | 17,296.00 |
| 10 | NextPlat | 24.77 Mn | 12.93 Mn | 4.69 Mn | 9,666.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 9,666.00 |
| Mar 31, 2026 | 2,867.00 |
| Dec 31, 2025 | 5,649.00 |
| Sep 30, 2025 | 6,978.00 |
| Jun 30, 2025 | 4,439.00 |
| Mar 31, 2025 | 940.00 |
| Dec 31, 2024 | 15,446.00 |
| Sep 30, 2024 | 5,288.00 |
| Jun 30, 2024 | 1,143.00 |
| Mar 31, 2024 | 4,651.00 |
| Dec 31, 2023 | 320.00 |
| Sep 30, 2023 | 5,184.00 |
| Jun 30, 2023 | -9,964.00 |
| Mar 31, 2023 | -2,092.00 |
| Dec 31, 2022 | -7,064.00 |
| Sep 30, 2022 | -6,863.00 |
| Jun 30, 2022 | -3,021.00 |
| Mar 31, 2022 | -504.00 |
| Dec 31, 2021 | -11,477.00 |
| Sep 30, 2021 | -7,971.00 |